U.S. markets open in 8 hours 12 minutes
  • S&P Futures

    4,367.00
    -36.75 (-0.83%)
     
  • Dow Futures

    34,030.00
    -223.00 (-0.65%)
     
  • Nasdaq Futures

    14,350.25
    -150.75 (-1.04%)
     
  • Russell 2000 Futures

    2,012.70
    -19.00 (-0.94%)
     
  • Crude Oil

    83.59
    +0.28 (+0.34%)
     
  • Gold

    1,840.50
    -1.20 (-0.07%)
     
  • Silver

    23.83
    +0.03 (+0.15%)
     
  • EUR/USD

    1.1321
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3481
    -0.0010 (-0.07%)
     
  • USD/JPY

    113.7700
    -0.1900 (-0.17%)
     
  • BTC-USD

    36,213.54
    +595.19 (+1.67%)
     
  • CMC Crypto 200

    822.11
    +11.51 (+1.42%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,090.07
    -498.30 (-1.81%)
     

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

·6 min read
8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • AUPH
  • AFMD
  • AXSM
  • BBIO
  • BEAM

The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022. Adaptimmune Therapeutics (NASDAQ: ADAP), a cellular immunotherapy company, has so far lost 47.4% of its value relative to its 52-week high in 2021.